Match Group Inc vs Nuwellis Inc — how do they compare? Match Group Inc trades at $39.02 (market cap $9.10B), while Nuwellis Inc trades at $2.84 (market cap $1.09M). The key difference: Match Group Inc is far larger — about 8348.6× Nuwellis Inc's market cap, and Match Group Inc pays a 2.05% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| MTCH | NUWE | |
|---|---|---|
Market Cap | $9.10B | $1.09M |
Sector | Media | Technology |
52-Week High | $40.29 | $527.46 |
52-Week Low | $28.90 | $2.80 |
Enterprise Value | $12.05B | -$722.58K |
Dividend Yield | 2.05% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NUWE trades at $3.00, up 5.26% today, following a 35:1 reverse stock split effective June 26, 2026. The company shows a low P/E of 0.06 and P/S of 0.01, but fundamentals are weak with a -217.22% net income margin and negative ROE. Recent news highlights patent awards and pediatric market expansion, yet cash flow remains negative. Analyst coverage is limited with a split buy/hold consensus.
Outlook is speculative; growth depends on successful commercialization of Aquadex therapy and cost management. Key risks include persistent losses, high cash burn, and competitive pressures. Investors should weigh low valuation against execution risks in the medical technology sector.
Trailing returns across standard periods
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →